2 recruiting, 1 completed. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Buzzard Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC Group 1-Isunakinra - Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Recruiting | University Health Network, Toronto | 60 | 2026-10-20 | 2026-10-29 |
| Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) isunakinra - Colorectal Cancer Metastatic | Phase 2 | Recruiting | Buzzard Pharmaceuticals | 20 | 2025-01-30 | 2026-10-23 |
| Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Isunakinra, PD-(L)1 Inhibitor - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Buzzard Pharmaceuticals | 15 | 2020-09-01 | 2024-08-06 |
Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
EBI-005 (2)
United States (2) · Canada (1)